ALLMedicine™ Anaplastic Oligodendroglioma Center

Sep 10th, 2021 - 89ZrZr-huJ591 immuno-PET targeting PSMA in IDH mutant anaplastic oligodendroglioma.|2021|Krebs S,Grommes C,McDevitt MR,Carlin SD,O'Donoghue JA,|

Jun 15th, 2021 - Anaplastic oligodendrogliomas are high-grade gliomas defined molecularly by 1p19q co-deletion. There is no curative therapy, and standard of care includes surgical resection followed by radiation and chemotherapy. However, the benefit of up-front ...

Mar 31st, 2021 - Treatment with temozolomide and BCNU was associated with substantial response and survival rates for patients with unresectable anaplastic glioma, suggesting potential therapeutic alternative for these patients. The optimal treatment for unresecta...

Jan 5th, 2021 - High-grade gliomas, including anaplastic oligodendroglioma, represent the most common malignant neoplasms of the central nervous system in the adult. The standard treatment of anaplastic oligodendroglioma consists of maximum surgical resection, ra...

Dec 2nd, 2020 - Coronavirus disease 2019 (COVID-19) has changed the way in which cancer is treated. Patients with high-grade glioma (HGG) are believed to be in a vulnerable category. The aim of this study was to describe the experience of a hub cancer center and ...

Sep 14th, 2013 - Primary and metastatic tumors of the central nervous system are a heterogeneous group of neoplasms with varied outcomes and management strategies. Recently, improved survival observed in 2 randomized clinical trials established combined chemothera...

Jul 31st, 2018 - Background Glioblastoma (GBM) is the most common primary brain tumor. With optimal treatment, consisting of focal radiotherapy with concurrent chemotherapy, followed by adjuvant chemotherapy, median survival is 14.6 months. Most patients have evid...

Mar 14th, 2017 - Phase I Primary Objective • To determine the maximum tolerated dose (MTD) of LBH589 in combination with bevacizumab given at 10 mg/kg every 2 weeks in patients with recurrent glioblastoma (GBM), gliosarcoma, anaplastic astrocytoma, anaplastic olig...

Jul 2nd, 2013 - High grade gliomas (HGGs) represent a heterogenous group of primary brain tumors that share WHO grade III or IV classification (anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic mixed glioma, and glioblastoma multiforme). Despite th...

Dec 5th, 2020 - The carcinoembryonic antigen (CEA) vaccinia has been researched for more than 20 years. Investigational Glioma Vaccine Results Promising A novel vaccine based on dendritic cells and peptides proved to be safe and capable of delivering an im...

Dec 5th, 2020 - Andrew L. Pecora, MD Editor-in-Chief Oncology & Biotech News Chief Innovations Officer, Professor, and Vice President of Cancer Services John Theurer Cancer Center at Hackensack University Medical Center I am sure any of ...

Dec 5th, 2020 - Victor A. Levin, MD Eflornithine (α-Difluoromethylornithine) has been investigated for over 30 years as a potential neuro-oncology agent and shown activity against recurrent gliomas, but it has not gained approval as a therapy option for patients...

Dec 5th, 2020 - Victor A. Levin, MD Investigators are seeking to determine whether the combination of eflornithine (alphadifluoromethylornithine) with lomustine can improve survival for patients with recurrent anaplastic astrocytoma (AA). A rare form of brain tu...

Jul 26th, 2012 - Andrew L. Pecora, MD Editor-in-Chief Oncology & Biotech News Chief Innovations Officer, Professor, and Vice President of Cancer Services John Theurer Cancer Center at Hackensack University Medical Center I am sure any of us can think of many other...